Thromboelastography (TEG)-based algorithm reduces blood product utilization in patients undergoing VAD implant

Area of Science:

• Cardiovascular Surgery
• Transfusion Medicine
• Coagulation Science

Background:

• Ventricular assist device (VAD) implantation often necessitates extensive blood product transfusions.
• Current transfusion practices typically rely on empirical guidance from conventional laboratory coagulation tests.
• Optimizing blood product utilization is crucial for patient outcomes and resource management in VAD surgery.

Purpose of the Study:

• To compare the efficacy of a thromboelastography (TEG)-based algorithm versus standard laboratory coagulation tests in guiding blood product utilization during and after VAD implantation.
• To evaluate the impact of a strict TEG-guided protocol on the consumption of various blood products.

Main Methods:

• Retrospective analysis of 39 consecutive patients undergoing VAD implantation between June 2010 and May 2012.
• Patients were divided into two groups: a control group (n=20) managed with standard coagulation tests and a TEG group (n=19) managed with a strict TEG-guided protocol.
• Perioperative coagulation parameters and blood product transfusions were documented and compared between the groups.

Main Results:

• The TEG group showed significantly reduced utilization of fresh-frozen plasma (intraoperative and postoperative) and platelets (postoperative and total).
• No significant difference in packed red blood cell consumption was observed between the groups.
• While Prothrombin time (PT) and international normalized ratio (INR) were higher post-protamine in the TEG group, no significant differences in postoperative coagulation variables were detected.

Conclusions:

• A strict thromboelastography (TEG)-guided algorithm effectively reduces the consumption of fresh-frozen plasma and platelets in patients undergoing VAD implantation.
• TEG-based transfusion protocols offer a more targeted approach to managing coagulopathy and optimizing blood product use in VAD surgery.
• Further research may explore the long-term clinical benefits and cost-effectiveness of TEG-guided transfusion strategies in this patient population.